Where we invest and how we create value
We focus on the segments of regulated healthcare manufacturing where barriers to entry are highest and operational expertise creates the most durable competitive advantage.
Sterile injectables for hospital formularies and specialty indications, targeting FDA and EMA-regulated markets where quality systems and supply reliability command premium positioning
Vaccine and biologic manufacturing platforms with established WHO prequalification, technology transfer capability, and fill-finish infrastructure.
Contract development and manufacturing organizations with regulated capabilities, strategic customer relationships, and untapped capacity optimization potential.
Implantable devices for critical care and vascular access, manufactured to ISO 13485 standards segments where clinical performance, sterility assurance and import substitution economics create defensible positions.
We pursue control positions in businesses where our operational involvement directly accelerates value creation not minority stakes where we are passengers.
Enabling us to set strategy, drive operational change, and make transformational decisions without friction
Expertise in acquiring businesses separated from larger pharmaceutical groups
Converting complexity into enterprise value
Parami combines disciplined investing, strategic direction and embedded operating leadership across every stage of ownership.
Deep operational assessments and lean manufacturing
implementation to structurally reduce cost of goods and
improve margin.
Investment in robust QMS infrastructure remediation, facility upgrades, and inspection readiness.
Restructuring supply chains for resilience and cost efficiency dual sourcing critical APIs and rationalising vendor bases.
Culling low-margin SKUs, prioritising high-value regulated market filings, and building development pipelines aligned to opportunity.
Developing market access strategies, customer relationships, and distribution partnerships for U.S. and European markets.
Localising production of imported critical-care products building domestic supply chains and machinery bases that structurally undercut import pricing while meeting international clinical standards.
